Product Overview
One-Injection Combination Hyaluronic Acid and Steroid
CINGAL is the first and only approved combination viscosupplement formulated to provide the benefit of a cross-linked hyaluronic acid (HA) and a fast acting steroid to effectively treat the symptoms associated with osteoarthritis (OA).
CINGAL is a powerful, first-in-class treatment that combines the benefits of Anika’s proprietary cross-linked hyaluronic acid formulation of MONOVISC®, proven to deliver up to 6 months of relief of the symptoms of OA, with a well-established FDA-approved steroid to treat inflammation and provide additional short-term pain relief.
CINGAL is Anika Therapeutics’ third-generation viscosupplementation product, adding to the Company’s strong product portfolio for the treatment of joint pain associated with OA. CINGAL extends the benefits of Anika’s proprietary HA formulation to a broader range of patients across the spectrum of osteoarthritis management.
The CINGAL Advantage
• In its pivotal clinical study, CINGAL has demonstrated an ability to provide fast and long-lasting pain relief for those affected by knee OA.
• Steroid provides fast short-term pain relief within days of injection
• HA viscosupplement provides long lasting pain relief, which may last through 6 months
• Convenient single-injection treatment
• Highly concentrated, non-animal based HA
• Strong safety profile in both an initial injection as well as a repeat injection (https://www.anikatherapeutics.com)
